Abstract:Smallcell lung cancer (SCLC) relapses in the majority of patients, even though most patients respond to firstline therapy. Subsequent therapy can provide significant palliation and prolongation of survival for many patients. At present, topotecan is considered the standard secondline chemotherapy. Recently, amrubicin has also shown more favorable antitumor activity, and is the most promising at present. Unfortunately, targeted agents have failed to demonstrate effectiveness for SCLC.

Key words:Small cell lung cancer,Recurrence,Treatment